Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).
Melissa Alsina
Consultant or Advisory Role - Millennium
Research Funding - Millennium
Paul Gerard Guy Richardson
Consultant or Advisory Role - Celgene; Johnson & Johnson; Millennium; Novartis
Robert L. Schlossman
Other Remuneration - Celgene; Millennium
Donna M. Weber
Consultant or Advisory Role - Novartis (U)
Research Funding - Novartis
Steven E. Coutre
No relevant relationships to disclose
Cristina Gasparetto
Consultant or Advisory Role - Celgene; Millennium; Novartis (I)
Honoraria - Novartis (I)
Sutapa Mukhopadhyay
Employment or Leadership Position - Novartis
Michael S. Ondovik
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Mahmudul H Khan
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Carole S. Paley
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Johnson & Johnson; Millennium; Novartis; Onyx; Sanofi